Canagliflozin 300mg

DRUG4 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen Research & Development, LLC, The University of Texas Health Science Center at San Antonio, Petra Pharma

Conditions

Breast CancerCardiovascular DiseasesColo-rectal CancerDiabetes Mellitus, Type 2Endometrial CancerHead and Neck CancerLung CancerType2 Diabetes Mellitus

Phase 1

A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

CompletedNCT01381887

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Diabetes Mellitus, Type 2

Start: 2011-06-30End: 2011-11-30Updated: 2013-04-22

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Petra PharmaBreast Cancer, Colo-rectal Cancer, Endometrial Cancer +2

Start: 2020-09-01End: 2021-12-30Target: 60Updated: 2020-05-21

Phase 3

A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

CompletedNCT01381900

Janssen Research & Development, LLCDiabetes Mellitus, Type 2

Start: 2011-08-31End: 2012-11-30Updated: 2014-05-09

Phase 4

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

WithdrawnNCT03190798

The University of Texas Health Science Center at San AntonioCardiovascular Diseases, Type2 Diabetes Mellitus

Start: 2017-09-01End: 2018-08-01Updated: 2017-10-12

Related Papers

Researchers Reveal Role of Super-Enhancers in Colorectal Cancer

Oncology Times2022-12-20